BioRegen
Irvine, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $420M
Overview
Creates allogeneic cell therapies to promote tissue repair in degenerative and inflammatory diseases.
Regenerative MedicineAutoimmuneOrthopedics
Technology Platform
A scalable platform for manufacturing engineered allogeneic mesenchymal stromal cells (MSCs) with enhanced therapeutic potency and consistency.
Funding History
1Total raised:$420M
Public Offering$420M
Opportunities
An aging population and rising prevalence of degenerative diseases create a large addressable market for regenerative therapies.
Risk Factors
Regulatory pathways for allogeneic cell therapies remain complex, and demonstrating durable efficacy in chronic conditions is challenging.
Competitive Landscape
Operates in a crowded field of cell therapy companies, competing on product durability, ease of administration, and manufacturing cost.